The hidden cardiac risk of a common painkiller
A large retrospective study of nearly 500 cancer patients receiving methadone for pain management has quantified the drug’s effect on heart rhythm. While high-dose methadone is known to prolong the QTc interval—a measure of the heart’s electrical cycle—this study focused on lower, analgesic doses. The analysis found a small but statistically significant increase in QTc interval of about 4 milliseconds one year after starting therapy. The risk was more pronounced in patients with pre-existing cardiac conditions, who saw an average increase of over 9 milliseconds. Overall, the proportion of patients with clinically significant QTc prolongation rose modestly from 3% at baseline to 6.8% after 12 months.
Why it might matter to you:
This research provides concrete, risk-stratified data on a cardiovascular side effect of a medication often used in chronic pain management. For a neuroscientist investigating pain mechanisms and treatments, understanding the systemic trade-offs of analgesic drugs is crucial. The findings advocate for a nuanced clinical approach, suggesting that routine cardiac monitoring may be most valuable for a specific subset of patients rather than being a universal requirement.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
